The Effective Way

COMPOSITION: Voglibose IP 0.2 mg + Metformin Hydrochloride IP 500 mg (SR)

• Type 2 diabetes mellitus (T2DM) is characterized by chronic hyperglycemia with insulin resistance and inadequate insulin secretion.
• In diabetic patients, Postprandial Hyperglycaemia (PPHG) is a direct and independent risk factor for the development of Cardiovascular Diseases (CVD) or stroke caused by premature atherosclerosis.
• Alpha-glucosidase inhibitors (AGIs) inhibit the enzyme α-glucosidase at the brush border of the intestinal epithelium, thus blocking the absorption of carbohydrates in the small intestine. They are administered with the first bite of a carbohydrate-containing meal and limit postprandial hyperglycemia without causing hypoglycemia.
• In a 24-week study on Korean patients with Type 2 DM  and with inadequate glycemic control on diet and exercise, treatment with voglibose and metformin provided superior glycemic control for HbA1c, 2h-PPG, and FPG levels, greater weight loss, and less glycemic variability than did metformin monotherapy.

INDICATIONS:

• Type-II Diabetes Mellitus
• Hyperglycaemia
• Diabetic Dyslipidemia